Regulatory, policy, and manufacturer news WHO influenza vaccine composition: WHO issued its recommendations for the 2026–2027 Northern Hemisphere seasonal influenza vaccine composition on 26 February 2026, including the...
Introduction When it comes to vaccines and vaccination, nothing worries patients more than potential side effects. The fear that vaccination could lead to death or disability dates back to the time of Jenner and has...
Vaccination in pregnancy has quietly become one of the most powerful tools we have to protect both mothers and their infants in the first months of life. During this period, infants are highly vulnerable to severe...
Respiratory syncytial virus (RSV) is an enveloped, negative-sense, single-stranded RNA pneumovirus with 2 key surface glycoproteins, the fusion (F) protein and the attachment (G) protein, which are the principal targets...
Overview The past week brought important signals on continental immunization strategies (Africa), local manufacturing (South Africa, India), next generation COVID-19 and mucosal vaccines (Europe, Asia–Pacific), and...
As the world reaches the midpoint of the Immunization Agenda 2030 (IA2030), immunization programs find themselves at an inflection point.1 The initial focus on recovering from pandemic-era backsliding is giving way to a...
North America – Politics First, Evidence Second US vaccine policy spent the week in committee rooms and courtrooms, as reforms to ACIP processes and federal advisory structures drew fire from professional societies and...
“Shared decision‑making” sounds benign, even progressive. Who would object to clinicians and families talking through risks and benefits together? Yet as it is currently being applied to vaccination, “shared...
What is EUVABECO? The EUVABECO project — short for European Vaccination Beyond COVID-19 — is a major initiative funded under the EU4Health programme, aiming to translate lessons from the COVID-19 pandemic into durable...
The processes around vaccine licensure today are still built on a shared core: robust evidence for quality, safety, and efficacy, demonstrated through standardized preclinical testing, phased clinical trials, and...